Sangil Lee1, Annie T Sadosty, Ronna L Campbell. 1. aDepartment of Emergency Medicine, Mayo Clinic Health System, Mankato bDepartment of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: Biphasic anaphylaxis is a well documented complication of anaphylaxis, but it has been inconsistently defined in the literature. Analysis of contemporary studies of biphasic anaphylaxis based on modern definitions is needed. RECENT FINDINGS: The rate of biphasic reactions in contemporary literature ranges from 0.4 to 14.7% depending on the study population. Observational studies have reported risk factors associated with the development of biphasic reactions; however, findings have been inconsistent and of questionable generalizability. Although life-threatening biphasic reactions are rare, up to 50% of biphasic reactions will require treatment with epinephrine. Early epinephrine administration may have a role in prevention of biphasic reactions, but the role of steroids needs further investigation. The optimal duration of observation is yet to be determined. SUMMARY: Given the relative rarity of life-threatening biphasic anaphylaxis and the new context of the NIAID/FAAN standardized definition, further research regarding biphasic anaphylaxis is needed to better elucidate the care model for anaphylaxis patients with a focus on: prevention of biphasic reactions; identification of patients at increased risk of a biphasic reaction; determination of appropriate observation strategies for anaphylaxis patients; and patient education and preparation for management of potential biphasic reactions.
PURPOSE OF REVIEW: Biphasic anaphylaxis is a well documented complication of anaphylaxis, but it has been inconsistently defined in the literature. Analysis of contemporary studies of biphasic anaphylaxis based on modern definitions is needed. RECENT FINDINGS: The rate of biphasic reactions in contemporary literature ranges from 0.4 to 14.7% depending on the study population. Observational studies have reported risk factors associated with the development of biphasic reactions; however, findings have been inconsistent and of questionable generalizability. Although life-threatening biphasic reactions are rare, up to 50% of biphasic reactions will require treatment with epinephrine. Early epinephrine administration may have a role in prevention of biphasic reactions, but the role of steroids needs further investigation. The optimal duration of observation is yet to be determined. SUMMARY: Given the relative rarity of life-threatening biphasic anaphylaxis and the new context of the NIAID/FAAN standardized definition, further research regarding biphasic anaphylaxis is needed to better elucidate the care model for anaphylaxis patients with a focus on: prevention of biphasic reactions; identification of patients at increased risk of a biphasic reaction; determination of appropriate observation strategies for anaphylaxis patients; and patient education and preparation for management of potential biphasic reactions.
Authors: Timothy E Dribin; Hugh A Sampson; Carlos A Camargo; David C Brousseau; Jonathan M Spergel; Mark I Neuman; Marcus Shaker; Ronna L Campbell; Kenneth A Michelson; Susan A Rudders; Amal H Assa'ad; Kimberly A Risma; Mariana Castells; Lynda C Schneider; Julie Wang; Juhee Lee; Rakesh D Mistry; David Vyles; Lisa M Vaughn; Daniel J Schumacher; John K Witry; Shiv Viswanathan; Erica M Page; David Schnadower Journal: J Allergy Clin Immunol Date: 2020-08-24 Impact factor: 10.793
Authors: Timothy E Dribin; Kenneth A Michelson; Michael C Monuteaux; Anne M Stack; Karen S Farbman; Lynda C Schneider; Mark I Neuman Journal: PLoS One Date: 2019-02-07 Impact factor: 3.240
Authors: Timothy E Dribin; Kenneth A Michelson; David Vyles; Mark I Neuman; David C Brousseau; Rakesh D Mistry; Peter S Dayan; Nanhua Zhang; Shiv Viswanathan; John Witry; Stephanie Boyd; David Schnadower Journal: BMJ Open Date: 2021-01-05 Impact factor: 2.692
Authors: Mitchell M Pitlick; Miguel A Park; Alexei Gonzalez-Estrada; Sergio E Chiarella Journal: Ann Allergy Asthma Immunol Date: 2021-07-31 Impact factor: 6.347